Hanem Sadek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hanem Sadek has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Chantal Lagresle-Peyrou
Paris Cité University, Imagine Institute, Paris, France
5 shared publications - Isabelle André-Schmutz
Paris Cité University, Imagine Institute, Paris, France
4 shared publications - Marina Cavazzana
Imagine Institute, Paris, France
4 shared publications - Amandine Durand
Human Lymphohaematopoiesis Laboratory, INSERM U1163, Paris, France
2 shared publications Myriam Chouteau
Laboratory of Human Lymphohematopoiesis, INSERM UMR 1163, Paris, France; Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France
2 shared publicationsSonia Luce
Laboratory of Human Lymphohematopoiesis, INSERM UMR 1163, Paris, France; Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France
2 shared publications
Latest Publications
- 21 December 2017
- Published by American Society of Hematology in Blood Advances
- Vol. 1 (27) , 2781-2789
Gene transfer into hematopoietic stem cells reduces HLH manifestations in a murine model of Munc13-4 deficiency
Patients with mutations in the UNC13D gene (coding for Munc13-4 protein) suffer from familial hemophagocytic lymphohistiocytosis type 3 (FHL3), a life-threatening immune and hyperinflammatory disorder. The only curative treatment is allogeneic hematopoietic stem cell (HSC) transplantation, although the posttreatment survival rate is not satisfactory. Here, we demonstrate the curative potential of UNC13D gene correction of HSCs in a murine model of FHL3. We generated a self-inactivating lentiviral vector, used it to complement HSCs from Unc13d-deficient (Jinx) mice, and transplanted the cells back into the irradiated Jinx recipients. This procedure led to complete reconstitution of the immune system (ie, to wild-type levels). The recipients were then challenged with lymphocytic choriomeningitis virus to induce hemophagocytic lymphohistiocytosis (HLH)–like manifestations. All the clinical and biological signs of HLH were significantly reduced in mice having undergone HSC UNC13D gene correction than in nontreated animals. This beneficial effect was evidenced by the correction of blood cytopenia, body weight gain, normalization of the body temperature, decreased serum interferon-γ level, recovery of liver damage, and decreased viral load. These improvements can be explained by the restoration of the CD8+ T lymphocytes’ cytotoxic function (as demonstrated here in an in vitro degranulation assay). Overall, our results demonstrate the efficacy of HSC gene therapy in an FHL-like setting of immune dysregulation. Key Points UNC13D gene transfer into HSCs corrects all clinical and biological signs of HLH in a mouse model. Munc13-4 is expressed in mature CD8+ T cells allowing the correction of cytotoxic activity and consequently efficient viral restriction. Visual Abstract
- 21 December 2017
- Published by American Society of Hematology in Blood Advances
- Vol. 1 (27) , 2781-2789
Gene transfer into hematopoietic stem cells reduces HLH manifestations in a murine model of Munc13-4 deficiency
Patients with mutations in the UNC13D gene (coding for Munc13-4 protein) suffer from familial hemophagocytic lymphohistiocytosis type 3 (FHL3), a life-threatening immune and hyperinflammatory disorder. The only curative treatment is allogeneic hematopoietic stem cell (HSC) transplantation, although the posttreatment survival rate is not satisfactory. Here, we demonstrate the curative potential of UNC13D gene correction of HSCs in a murine model of FHL3. We generated a self-inactivating lentiviral vector, used it to complement HSCs from Unc13d-deficient (Jinx) mice, and transplanted the cells back into the irradiated Jinx recipients. This procedure led to complete reconstitution of the immune system (ie, to wild-type levels). The recipients were then challenged with lymphocytic choriomeningitis virus to induce hemophagocytic lymphohistiocytosis (HLH)–like manifestations. All the clinical and biological signs of HLH were significantly reduced in mice having undergone HSC UNC13D gene correction than in nontreated animals. This beneficial effect was evidenced by the correction of blood cytopenia, body weight gain, normalization of the body temperature, decreased serum interferon-γ level, recovery of liver damage, and decreased viral load. These improvements can be explained by the restoration of the CD8+ T lymphocytes’ cytotoxic function (as demonstrated here in an in vitro degranulation assay). Overall, our results demonstrate the efficacy of HSC gene therapy in an FHL-like setting of immune dysregulation. Key Points UNC13D gene transfer into HSCs corrects all clinical and biological signs of HLH in a mouse model. Munc13-4 is expressed in mature CD8+ T cells allowing the correction of cytotoxic activity and consequently efficient viral restriction. Visual Abstract
- 1 December 2016
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 138 (6) , 1681-1689.e8
X-linked primary immunodeficiency associated with hemizygous mutations in the moesin (MSN) gene
- 1 December 2016
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 138 (6) , 1681-1689.e8
X-linked primary immunodeficiency associated with hemizygous mutations in the moesin (MSN) gene
- Open Access
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S168
425. Production of Gene Corrected T Cell Precursors for Therapy of SCID X1
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S168
Open Access425. Production of Gene Corrected T Cell Precursors for Therapy of SCID X1
- Open Access
- 13 August 2015
- Published by Springer Nature in Cell Death & Disease
- Vol. 6 (8) , e1856
AK2 deficiency compromises the mitochondrial energy metabolism required for differentiation of human neutrophil and lymphoid lineages
Reticular dysgenesis is a human severe combined immunodeficiency that is primarily characterized by profound neutropenia and lymphopenia. The condition is caused by mutations in the adenylate kinase 2 (AK2) gene, resulting in the loss of mitochondrial AK2 protein expression. AK2 regulates the homeostasis of mitochondrial adenine nucleotides (ADP, ATP and AMP) by catalyzing the transfer of high-energy phosphate. Our present results demonstrate that AK2-knocked-down progenitor cells have poor proliferative and survival capacities and are blocked in their differentiation toward lymphoid and granulocyte lineages. We also observed that AK2 deficiency impaired mitochondrial function in general and oxidative phosphorylation in particular – showing that AK2 is critical in the control of energy metabolism. Loss of AK2 disrupts this regulation and leads to a profound block in lymphoid and myeloid cell differentiation.
- 13 August 2015
- Published by Springer Nature in Cell Death & Disease
- Vol. 6 (8) , e1856
Open AccessAK2 deficiency compromises the mitochondrial energy metabolism required for differentiation of human neutrophil and lymphoid lineages
Reticular dysgenesis is a human severe combined immunodeficiency that is primarily characterized by profound neutropenia and lymphopenia. The condition is caused by mutations in the adenylate kinase 2 (AK2) gene, resulting in the loss of mitochondrial AK2 protein expression. AK2 regulates the homeostasis of mitochondrial adenine nucleotides (ADP, ATP and AMP) by catalyzing the transfer of high-energy phosphate. Our present results demonstrate that AK2-knocked-down progenitor cells have poor proliferative and survival capacities and are blocked in their differentiation toward lymphoid and granulocyte lineages. We also observed that AK2 deficiency impaired mitochondrial function in general and oxidative phosphorylation in particular – showing that AK2 is critical in the control of energy metabolism. Loss of AK2 disrupts this regulation and leads to a profound block in lymphoid and myeloid cell differentiation.
- 1 July 2014
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 134 (1) , 145-154.e3
The BLNK adaptor protein has a nonredundant role in human B-cell differentiation
- 1 July 2014
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 134 (1) , 145-154.e3
The BLNK adaptor protein has a nonredundant role in human B-cell differentiation